Abstract
Background: The recently published Clinical Practice Guidelines (CPGs) for the treatment of stages I–IV periodontitis provided evidence-based recommendations for treating periodontitis patients, defined according to the 2018 classification. Peri-implant diseases were also re-defined in the 2018 classification. It is well established that both peri-implant mucositis and peri-implantitis are highly prevalent. In addition, peri-implantitis is particularly challenging to manage and is accompanied by significant morbidity. Aim: To develop an S3 level CPG for the prevention and treatment of peri-implant diseases, focusing on the implementation of interdisciplinary approaches required to prevent the development of peri-implant diseases or their recurrence, and to treat/rehabilitate patients with dental implants following the development of peri-implant diseases. Materials and Methods: This S3 level CPG was developed by the European Federation of Periodontology, following methodological guidance from the Association of Scientific Medical Societies in Germany and the Grading of Recommendations Assessment, Development and Evaluation process. A rigorous and transparent process included synthesis of relevant research in 13 specifically commissioned systematic reviews, evaluation of the quality and strength of evidence, formulation of specific recommendations, and a structured consensus process involving leading experts and a broad base of stakeholders. Results: The S3 level CPG for the prevention and treatment of peri-implant diseases culminated in the recommendation for implementation of various different interventions before, during and after implant placement/loading. Prevention of peri-implant diseases should commence when dental implants are planned, surgically placed and prosthetically loaded. Once the implants are loaded and in function, a supportive peri-implant care programme should be structured, including periodical assessment of peri-implant tissue health. If peri-implant mucositis or peri-implantitis are detected, appropriate treatments for their management must be rendered. Conclusion: The present S3 level CPG informs clinical practice, health systems, policymakers and, indirectly, the public on the available and most effective modalities to maintain healthy peri-implant tissues, and to manage peri-implant diseases, according to the available evidence at the time of publication.
| Original language | English |
|---|---|
| Pages (from-to) | 4-76 |
| Number of pages | 73 |
| Journal | Journal of Clinical Periodontology |
| Volume | 50 |
| Issue number | S26 |
| DOIs | |
| Publication status | Published - Jun 2023 |
Bibliographical note
Publisher Copyright:© 2023 The Authors. Journal of Clinical Periodontology published by John Wiley & Sons Ltd.
Funding
(Chair) reports—Grants or contracts from any entity: Osteology Foundation, ITI, Oral Reconstruction Foundation (Contract via University); Camlog, Straumann, Geistlich, Dentsply (Contract via University); BMBF and Dentsply (Contract via University—Grant to investigate surgical peri‐implantitis therapy by combination of a plasma and a water jet). Consulting fees: Henry Schein (Personal Honoraria). Payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing, or educational events: Osteology Foundation, ITI, Oral Reconstruction Foundation (Personal lecture fees); Camlog, Straumann, Geistlich (Personal lecture fees). Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: Osteology Foundation (Annual compensation fee); EAO (unpaid). Receipt of equipment, materials, drugs, medical writing, gifts or other services: Straumann, Camlog, Geistlich, Dentsply (Receipt of equipment, materials in association with research contracts via university). Frank Schwarz (Chair) reports—Grants or contracts from any entity: Grant from GSK (PhD studentship & other grants); Two grants from DEBRA (Epidermolysis Bullosa Charity), one grant from Unilever (Research Grants); NIHR Biomedical Research Centre Grant (Research infrastructure grant). Royalties or licences: Quintessence (Book Royalties). Consulting fees: J&J, GSK, Unilever, Philips (Consultancy Fees). Payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing, or educational events: J&J, GSK, Unilever, Philips (Sponsored Lecture Fees); Lectures to Swiss, German, Italian, Portuguese, Turkish, Polish, Danish, Austrian, British societies, IAP Colombia (Expenses paid for meetings). Support for attending meetings and/or travel: P&G, J&J (Support to participate in international conference). Patents planned, issued, or pending: 65 patents (Patents on saliva diagnostics). Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: European Workshop Committee of the EFP—co‐chair; Invited member of EFP Executive Board (Unpaid); Chair of FDI WG on Oral & Systemic Health (Unpaid); Scientific Advisor to the British Society of Periodontology Executive Board (Unpaid). Other financial or non‐financial interests: non‐financial (wife runs Oral Health Innovations, which has the licence for PreViser and DEPPA risk assessment software in the UK). Iain Chapple The authors express their gratitude to all reviewers involved in the preparation of the SRs and sincerely thank those organizations that participated in the guideline development process: Council of European Dentists, European Dental Hygienists Federation, European Dental Students' Association, European Society for Endodontology, Platform for Better Oral Health in Europe. (Chair) reports—Grants or contracts from any entity: ITI, Straumann, Geistlich, GC, Regedent AG, Research Grant by the University of Bristol and GlaxoSmithKline, Oral Reconstruction Foundation, Association for Dental Infection Control (Research contract via university). Payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing, or educational events: Osteology Foundation, Geistlich, Straumann, Regedent AG, Camlog, Oral Reconstruction Foundation, EMS, German Society of Periodontology (DGParo), Danish Dental Association (Honoraria for lectures). Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: Osteology Foundation (Honorarium for Board Meeting); Swiss Dental Society (SSO) (Bernese Section) (Honorarium for Board Meeting). (Chair) reports—Grants or contracts from any entity: Straumann AG, Geistlich AG, Sunstar SA (Grant). Payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing, or educational events: Straumann AG (Sunstar SA); Nobel Biocare, Hu‐friedy; Geistlich AG (honoraria for lectures). Leadership or fiduciary role in another board, society, committee or advocacy group, paid or unpaid: European Research Group on Periodontology, Executive Director (Unpaid). Receipt of equipment, materials, pharmaceuticals, medical writing, gifts, or other services: Straumann AG; Geistlich AG. Anton Sculean Maurizio Tonetti
| Funders | Funder number |
|---|---|
| Council of European Dentists | |
| Epidermolysis Bullosa Charity | |
| European Dental Hygienists Federation | |
| European Dental Students' Association | |
| European Society for Endodontology | |
| GlaxoSmithKline | |
| Unilever | |
| Dystrophic Epidermolysis Bullosa Research Association | |
| Manchester Biomedical Research Centre | |
| GlaxoSmithKline España | |
| University of Bristol | |
| Bundesministerium für Bildung und Forschung | |
| Osteology Foundation | |
| International Team for Implantology |
ASJC Scopus Subject Areas
- Periodontics